A phase I open-label, single-arm, dose escalation study of E7107 administered intravenously on days 1 and 8 every 21 days to patients with solid tumors.

Trial Profile

A phase I open-label, single-arm, dose escalation study of E7107 administered intravenously on days 1 and 8 every 21 days to patients with solid tumors.

Suspended
Phase of Trial: Phase I

Latest Information Update: 22 Nov 2013

At a glance

  • Drugs E 7107 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Most Recent Events

    • 21 Nov 2009 New source identified and integrated (M.D. Anderson Cancer Center).
    • 03 Feb 2009 Status changed from recruiting to suspended, according to ClinicalTrials.gov.
    • 24 Jun 2008 The expected completion date for this trial is Aug 2010 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top